The present disclosure provides complexes and compositions comprising particles, microparticles or nanoparticles, for delivery of payloads into a cell or across a polarized epithelial cell. The compositions can comprise a payload in a pill or tablet for delivery of the payload into or across a polarized epithelial cell.

Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies secreted by human B lymphocytes. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.

Dehydrated biofilm assemblies and methods for manufacturing dehydrated biofilm assemblies are disclosed. An example dehydrated biofilm assembly may include a dehydrated biofilm assembly for use in antimicrobial testing. The dehydrated biofilm assembly may include a substrate and a dehydrated biofilm secured to the substrate. The dehydrated biofilm may include a viable population of micro-organisms. The dehydrated biofilm may be configured to retain securement to the substrate and exhibit a biofilm phenotype upon hydration.

Non-naturally occurring vesicles derived from bacteria, e.g., pathogenic bacteria, methods for making the vesicles, and methods for using compositions of these vesicles are disclosed. Methods of using the vesicles include prevention and/or treatment of bacterial infections. Also provided herein are compositions that include vesicles derived front bacteria and tumor vesicles, methods for making the tumor vesicles, and methods for using the compositions of bacterial vesicles and tumor vesicles. Methods of using the compositions of bacterial vesicles and tumor vesicles include treatment of cancer in a subject. Tumor vesicles may be derived from cancer cells present in the subject to be treated or from a cancer cell line expressing at least one neoantigen. The neoantigen may be specific to the subject and may have been identified by sequencing of the cancer cells from the subject. The neoantigen may be a neoantigen known to be commonly expressed in a particular type of cancer.

The present disclosure provides a process for preventing, and alleviating citrus greening infection of citrus plants including identifying the causative agent, providing consortia comprising Trichoderma spp. and Pseudomonas spp. in definite ratios effective in targeting the causative agent Phytophthora spp. and thereby preventing or alleviating the citrus greening disease in an effective manner. The present disclosure also provides consortia comprising standardized cultures of Trichoderma spp. in varying ratios and Pseudomonas spp. in varying ratios effective in preventing and controlling the causative agent Phytophthora spp. at different ages of citrus plants and stages of infection. The present disclosure further provides formulations comprising the antagonist microbial consortia and tailor made kits comprising one or more formulations of the present disclosure for managing citrus greening disease.

A generic type I CRISPR-Cas-based genome-editing system that can be used in microbial hosts having diverse genetic backgrounds has been established. The chromosomal integration system overcomes the limitations of narrow host range and the requirement for antibiotics to maintain propagation and expression which are associated with plasmid-encoded Cas proteins. Compositions and methods for a chromosomal integrated type I-F CRISPR-Cas system for programmable genome editing and robust gene regulation are provided. In some embodiments, the compositions and methods are effective to selectively and specifically edit and/or regulate the genome of multiple microbial species with diverse genotypes. Compositions and methods for gene editing and/or gene regulation in Pseudomonas spp, such as multiple strains of P. aeruginosa, are described.

Process for producing a rhamnolipid produced by Pseudomonas or Enterobacter using andiroba or murumuru seed waste, pertaining to the sector of compounds containing monosaccharide radicals, consists of producing rhamnolipids by a biotechnological process using andiroba or murumuru seed waste, following oil extraction, as a substrate for a Pseudomonas aeruginosa, Enterobacter hormaechei or Enterobacter buriae line cultivated in a bioreactor with a non-dispersive aeration system for reducing foam, producing a rhamnolipid content of 10.5 g/L for Pseudomonas aeruginosa bacteria, in bioreactors carried out in a stirred tank with non-dispersive aeration using microporous membranes, particularly of silicone tubes, which allow oxygen to be supplied by diffusion. This type of aeration allows for various configurations, and in the embodiment of the invention, the porous membrane/tube was internally located in the liquid in the bioreactor in the form of a serpentine, under the following process conditions: pure oxygen with suitable pressure and flow rate to maintain O2 pressure in the bioreactor at 20% during the first 24 hours of the assay and stirring varying from 300 to 700 rpm, using 2 radial impellers and manual adjustment according to the decrease in the concentration of dissolved oxygen. The product produced has features that can be used primarily in the cosmetic industry due to its emulsifying, stability and non toxicity capacities.

The present invention discloses a strain of Pseudomonas aeruginosa with monomethylamine degradability and the application thereof. This strain, named Pseudomonas aeruginosa GDUTAN1, was deposited on May 24, 2017 in the China Center for Type Culture Collection in Wuhan University, Wuhan City, Hubei Province with a deposit number of CCTCC NO.: M 2017283. This Pseudomonas aeruginosa GDUTAN1 was Gram-negative and rod-like, and round, green and opaque in the colony morphology, having a diameter of 1-2 mm. The Pseudomonas aeruginosa GDUTAN1 of the present invention can be applied to environmental remediation, degrading monomethylamine in the environment at a high degradation efficiency. When it degrades monomethylamine for 96 h at a substrate concentration of 50-140 mg/L, the degradation efficiency can reach more than 99%.

The present invention refers to a method for the production of live attenuated bacterial strains, suitable as vaccine candidates, comprising the steps of: A. providing a bacterial strain capable of expressing glutamate racemase and possibly D-amino acid transaminase and comprising a peptidoglycan cell wall, and B. inactivating the gene or genes encoding for the glutamate racemase enzyme and, if needed, the gene or genes encoding for the enzyme D-amino acid transaminase in such way that the bacterial strain is no longer capable of expressing a functional glutamate racemase and/or a functional D-amino acid transaminase;
wherein the inactivation of said genes causes said bacterial strain to be auxotrophic for D-glutamate.

Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies secreted by human B lymphocytes. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.